Bioxcel Therapeutics Inc

This study tested a new oral drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the right dose and see if the combo can shrink tumors or slow the disease. Participa…

This study tested a medicine called BXCL501 for calming sudden episodes of agitation in people with dementia. 151 participants took the medicine as needed over 12 weeks. The goal was to see if it safely reduces symptoms like tension and hostility.

This study tested an investigational medication called BXCL501 for calming agitation episodes in people with bipolar disorder, schizophrenia, or related conditions. 452 adults took either the drug or a placebo, and researchers measured changes in agitation levels and safety. The …

This study looked at what happens when people with schizophrenia or bipolar disorder take Igalmi repeatedly for agitation over 7 days, and then stop. Researchers wanted to see if the drug becomes less effective (tolerance) or causes withdrawal symptoms. 29 adults participated in …

This study looked at whether family members or caregivers can help measure agitation in people with bipolar disorder or schizophrenia. 33 adults took a single dose of an experimental medicine, and researchers compared ratings from doctors, patients, and their family members. The …